Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | MAPT | P10636 | 8/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 3/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282643 | 0.88 | POLB (0.81) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4282964 | 0.87 | KDM4E (0.81) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318629 | 0.85 | POLB (0.76) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318590 | 0.85 | MEN1 (0.80) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4286601 | 0.84 | RAB9A (0.67) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318499 | 0.84 | MAPT (1.00) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4282129 | 0.84 | POLB (0.63) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318501 | 0.84 | KDM4E (0.76) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318502 | 0.84 | KDM4E (1.00) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL17318527 | 0.83 | POLB (0.69) | POLBMEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | SIERRA SCIENCES, LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | SIERRA SCIENCES, LLC | 2025-06-05 | — | — | US | disclosed |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | SIERRA SCIENCES INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179122-A1 | Telomerase Reverse Transcriptase (TERT) Expression Enhancing Compounds and Methods for Using the Same | TERT, RNGTT, TERF2 | POLB 29/4885MEN1 3080/4885KMT2A 455/4885 |
| US-12404304-B1 | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same | TERT, TELO2, POT1 | POLB 284/4885MEN1 4306/4885KMT2A 273/4885 |
| US-20090143451-A1 | COMPOUNDS THAT INCREASE TELOMERASE REVERSE TRANSCRIPTASE (TERT) EXPRESSION AND METHODS FOR USING THE SAME | TERT, TERF2, RNMT | POLB 24/4885MEN1 3190/4885KMT2A 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.